drugset / Trial / NCT05542849

The Efficacy and Tolerability of Acarbose in Healthy Individuals

NCT05542849

Phase 4 Completed 15 enrolled AgelessRx
Non-randomizedParallel-groupOpen-labelPrevention

Summary

A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.

Timeline

Start
2022-08-10
Primary completion
2022-10-05
Completion
2022-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown 50 mg

Indications

No indication recorded.